發(fā)布時(shí)間：2018-03-06 05:07

  本文選題：利奈唑胺　切入點(diǎn)：替考拉寧　出處：《中國(guó)抗生素雜志》2016年10期 　論文類型：期刊論文

【摘要】：目的根據(jù)抗菌藥物的藥動(dòng)學(xué)/藥效學(xué)基本原理,應(yīng)用蒙特卡洛模擬法優(yōu)化利奈唑胺、替考拉寧和萬(wàn)古霉素治療MRSA感染的給藥方案。方法從已發(fā)表文獻(xiàn)中獲得利奈唑胺、替考拉寧和萬(wàn)古霉素在重癥監(jiān)護(hù)病房(ICU)患者中的藥動(dòng)學(xué)參數(shù),從ECUST網(wǎng)站獲得耐甲氧西林金黃色葡萄球菌(MRSA)對(duì)3種藥物最低抑菌濃度值的分布。采用蒙特卡洛模擬法計(jì)算不同給藥方案的目標(biāo)獲得概率和累積反應(yīng)分?jǐn)?shù)。結(jié)果收集的數(shù)據(jù)表明,利奈唑胺、替考拉寧和萬(wàn)古霉素在ICU患者中的藥動(dòng)學(xué)參數(shù)變化差異大。經(jīng)模擬分析,利奈唑胺、替考拉寧、萬(wàn)古霉素3種藥物分別以600mg/bid、500mg/qd、750mg/bid靜脈輸注的給藥方案,對(duì)MRSA的治療是合理的。同時(shí)臨床上應(yīng)根據(jù)MRSA病原菌對(duì)藥物的敏感性調(diào)整給藥方案。結(jié)論利用抗菌藥物PK/PD基本原理結(jié)合蒙特卡洛模擬法,可優(yōu)化利奈唑胺、替考拉寧和萬(wàn)古霉素用于MRSA經(jīng)驗(yàn)治療的給藥方案,為臨床提供參考。
[Abstract]:Objective according to the pharmacokinetic / pharmacodynamic principles of antimicrobial agents, monte Carlo simulation was used to optimize the regimen of linazolamide, teicoplanin and vancomycin in the treatment of MRSA infection. Pharmacokinetic parameters of teicoplanin and vancomycin in patients with ICU in intensive care unit, The distribution of minimum inhibitory concentration of methicillin-resistant Staphylococcus aureus to three drugs was obtained from the ECUST website. Monte Carlo simulation was used to calculate the target acquisition probability and cumulative response score of different drug delivery schemes. The pharmacokinetic parameters of linazolamide, teicoplanin and vancomycin varied greatly in ICU patients. The treatment of MRSA is reasonable and the regimen of administration should be adjusted according to the sensitivity of MRSA pathogens to drugs. Conclusion the basic principle of antimicrobial drug PK/PD combined with Monte Carlo simulation method can optimize the efficacy of linazolamide. Teicoplanin and vancomycin were used in the treatment of MRSA.
【作者單位】： 西安市第一醫(yī)院藥劑科;
【分類號(hào)】：R459.7
，

本文編號(hào)：1573429